Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. | ...

Johnson & Johnson has put forward a clinical study exploring the use of its Shockwave Medical division’s vessel-clearing ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

RegenXBio will fill its coffers with up to $250 million by monetizing more royalty rights for Novartis-partnered Zolgensma, ...

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...